Sarepta Therapeutics | SRPT - 税前利润



金融业
股票价格
USD
资产
USD 3.18B
现金及等价物
USD 464.45M
销售成本
USD 109.46M
流动资产
USD 2.31B
流动负债
USD 499.16M
债务
USD 1.04B
EBIT
USD 358.43M
EBITDA
USD -252.2M
员工
1.37K
EPS每股收益
USD 3.16
股本和储备
USD 1.51B
销售毛利
USD 621.34M
债务利息支出
USD 20.84M
利息收入
USD 8.74M
贷款资金
USD 838.16M
市值
USD 1.49B
净收入
USD 330.96M
营业费用
USD 372.37M
营业利润
USD 358.43M
普通股股本
USD 105.57M
PE价格收益
27.27
税前利润
USD 343.17M
销售收入
USD 730.8M
销售和管理费用
USD 54.03M
股票
USD 1B
贸易债权人
USD 70.38M
应收帐款人
USD 547.91M


税前利润 更改 日
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amgen USD 2.08B 570M 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Capricor Therapeutics USD -30.17M 5.6M 2025-12
Daiichi Sankyo JPY -6.52B 113.25B 2026-03
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD -7.53B 10.11B 2026-06
Incyte USD 751.51M 407.91M 2026-06
Insmed USD -162.1M 164.84M 2026-03
Ionis Pharmaceuticals USD -114M 21M 2026-06
Moderna USD -1.33B 535M 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR 837M 1.17B 2026-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Tectonic Therapeutic USD -18.97M 63K 2025-12
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03